An uneventful case demonstrates feasibility, not comparative neurological safety.
The patient had MOG-antibody-associated disease with a history of anti-NMDA-receptor encephalitis and underwent elbow surgery. The anesthetic plan included steroid coverage, remimazolam, remifentanil and monitored neuromuscular blockade. Recovery was described as uncomplicated.
One patient cannot establish the preferred anesthetic for demyelinating disease or measure relapse risk. Concurrent treatment and careful monitoring were part of the intervention. The absence of a complication cannot be assigned solely to the benzodiazepine.
For a neurological-anesthesia opinion, separate baseline disease activity, immunotherapy, seizure history and anesthetic exposure. Identify how recovery and later symptoms were assessed. This report supports a limited clinical observation and cannot establish that remimazolam prevents relapse or is superior to regional or alternative general anesthesia.
Source reviewed: General anesthesia using remimazolam for the patient with myelin oligodendrocyte glycoprotein antibo (PMC9678535). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: A Dialysis Patient’s Later Remimazolam Course Followed a Prior Anesthetic Arrest.